EUCTR2020-002798-92-BE进行中（未招募）1 期
A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents with Recent-Onset Type 1 Diabetes Mellitus - PROTECT Extension Study
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 188
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Completion of the PRV-031-001 (PROTECT) study by completing the Week 78 visit in that study, regardless of how many doses of study drug were administered.
- •2. Provide written informed consent within 12 months of the Week 78 in the PRV-031-001 study. Written assent will be obtained for participants under 18 years of age at the time of enrollment, according to applicable regulations. If possible, written informed consent and/or assent for the current PROTECT Extension study (PRV-031-003) should be obtained at the final (Week 78) visit in the PROTECT study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 175
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Premature discontinuation from the PRV-031-001 study for any reason.
研究者
相似试验
进行中（未招募）
1 期
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of TeplizumabType 1 Diabetes (T1D)MedDRA version: 20.0Level: LLTClassification code 10012594Term: DiabetesSystem Organ Class: 100000004861EUCTR2020-002798-92-PLProvention Bio, Inc.200
进行中（未招募）
1 期
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of TeplizumabType 1 Diabetes (T1D)MedDRA version: 20.0Level: LLTClassification code 10012594Term: DiabetesSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-002798-92-DEProvention Bio, Inc.188
招募中
3 期
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of TeplizumabType 1 Diabetes Mellitus2024-516543-26-00Provention Bio Inc.66
进行中（未招募）
1 期
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of TeplizumabType 1 Diabetes (T1D)MedDRA version: 20.0Level: LLTClassification code 10012594Term: DiabetesSystem Organ Class: 100000004861EUCTR2020-002798-92-FRProvention Bio, Inc.200
进行中（未招募）
不适用
A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus - Protégé ExtensioEUCTR2008-008432-82-CZMacroGenics, Inc.538